CeriBell, Inc. (CBLL) Earnings Call Transcript
May 11, 2026
Earnings Call Speaker Segments
Good afternoon, everyone, and thanks for joining us on today's call. With me from Ceribell are Jane Chao, our Co-Founder and Chief Executive Officer, and Scott Blumberg, our Chief Financial Officer. Earlier today, Ceribell put out a press release with its financial results for the quarter that ended March 31, 2026. You can find a copy of that press release in the Investor Relations section of the company's website. Before we get started, I want to remind you that during this call, management will make remarks that include forward-looking statements under the meaning of federal securities laws, and that these statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements on this call relating to expectations or predictions of future events, results or performance are forward-looking statements. Such statements involve material risks and uncertainties that could cause actual results or events to differ materially from those anticipated or implied by these forward-looking statements. So you should not place undue reliance on them. For a list and description of the risks and uncertainties associated with our business, please see the Risk Factors section of our public filings with the Securities and Exchange Commission, including our annual report on Form 10-K filed with the SEC on February 24, 2026. This conference call contains time-sensitive information and is accurate only as of the live broadcast today, May 11, 2026. Except as required by law, Ceribell disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether because of new information, future events or otherwise. With that, I'll hand the call over to Jane.
Good afternoon, everyone, and thanks for being with us on this call covering our first quarter of 2026 results. We had a robust Q1, posting $26.5 million in revenue, which rose 29% compared with the same period a year ago and 7% over the prior quarter. The gains came from record utilization of our headbands along with our biggest quarter ever for net new accounts added. Gross margin came in at 87%, and we anticipate keeping it within the high 80s range for all of 2026. In addition to making further headway penetrating our primary seizure market, we reached 2 significant milestones that represent turning points as our platform evolves. First, after a successful pilot, we have kicked off the complete commercial rollout of our neonate and pediatric offerings. It is a privilege to extend our seizure monitoring solution to some of the most vulnerable patients. Second, we went live at the initial site for our delirium pilot during April, which marks our entrance into the $1 billion market where our FDA-cleared diagnostic tool is the only one available. I'll go into detail on both milestones soon. To begin, let me cover how we performed in our core market. Our aim is to establish ourselves as the standard of care for seizure management across the 6,000 U.S. hospitals providing acute care services. Our strategy for growth involves two main avenues: acquiring new customers and increasing usage among the hospitals that already have our products in place. On the customer acquisition side, we wrapped up the first quarter with 680 hospitals actively utilizing the Ceribell System. With 33 net new accounts added, it marked our best quarter for growth in accounts since becoming a public company, and we remain confident that we can exceed our 2025 figures for new additions during 2026. This optimism is grounded in three key advantages within this part of our business: the continued development of our recently expanded sales force, deeper penetration into the VA and other health systems, and a substantial pipeline of pending accounts. The build-out of our account acquisition team that kicked off in Q4 2024 is delivering results. Of the new hires who have been with us at least 12 months, more than 85% have helped build the active account base, and 100% have produced purchase orders. Considering how our sales cycle is timed and how long it takes to bring new accounts online, this productivity level is encouraging. As additional new hires gain experience over the course of 2026, we look for productivity to step up further, with even more acceleration during 2027. In addition to expanding the territory manager team, we're building momentum on 2 efforts aimed at speeding up hospital system acquisition. First, we anticipate ongoing momentum in the VA system, where we are still in the early phases of penetrating the 170 hospitals that our FedRAMP High Authorization unlocked last year. On a separate note, building on what we achieved with the VA, we started a pilot at certain U.S. military hospitals. The scale of this opportunity is incremental, yet even so, it provides compelling validation of our product and of our standing as a category leader. Additionally, we've brought on board a compact group dedicated to pursuing top-down partnerships with regional hospital networks; this works alongside the grassroots efforts of our TM team and creates more routes toward adoption at the system level. On the whole, we're heartened by how the market is increasingly embracing our technology, and we're happy with how our team is building momentum in securing new accounts. At the same time, same-store growth patterns continue to be robust. During Q1, we saw our best quarter yet when it comes to headband usage per account. Our expanding CAM team keeps pushing utilization higher via departmental growth, engaging providers across every shift and backing protocol development. We think there's a substantial chance to push utilization up even more. Among accounts that have embraced our best practices, the outcomes demonstrate this clearly. When you look at our top-tier accounts, they tend to handle about three times as many patients as what you'd see at a typical account. And honestly, what we keep hearing from people using our product out in the field just makes us more encouraged. The bigger our user community gets and the more real-world evidence accumulates, the more people recognize why measurable brain monitoring right at the patient's bedside is clinically essential. This past March, I witnessed that firsthand at the Society of Critical Care Medicine's Annual Meeting. The excitement around what we've built was sky-high — far beyond anything we'd experienced at earlier conferences in this space. You can see we're inching closer to our goal of helping change how seizure care is practiced. Let me now turn to our programs for seizures in neonates and pediatric patients. The commercial rollout for our two products has officially begun. When it comes to the Neonate group, improving how seizures are managed has the potential to change the entire course of someone's life. Five sites hosted our pilot program, which included a blend of customers we already had and some who were new to us. Today, every one of those five hospitals is moving ahead from the pilot phase into full implementation. This kind of momentum bolsters the clinical case for applying our technology to younger patients, as well as the business opportunities on the horizon. Our pediatric launch remains at an early point, but what we've been hearing from parents and doctors is already incredibly meaningful. I'd like to walk through a recent situation involving a pediatric patient who came into the emergency department. A mom rushed her 2-year-old son into the emergency room, where he arrived unresponsive. That marked his second trip to the ER that same day. At the bedside, the provider initially struggled to identify what was actually driving the problem, until a neurologist requested the Ceribell System. Seizure activity showed up immediately through Clarity, and neurologists verified it. As a result, there was no need for a lumbar puncture, nor a potential ICU stay while waiting on a conventional EEG. Treatment could start without delay, and by later that day the boy was fully alert again. The next morning, he left for home. What this case illustrates is precisely what the Ceribell System was designed to do: catch seizure activity fast, guide treatment decisions as they happen, and get patients the care they require sooner. Turning to delirium now. We were really pleased in April to get our delirium pilot's first site up and running. At Ceribell, this marks the start of a new phase as we keep working to establish EEG as a vital sign. As a reminder, once we received FDA 510(k) clearance in December, Ceribell became the first and only company with an FDA-cleared solution for monitoring delirium. Delirium is the neurological complication seen most often in the ICU, yet the way it gets assessed today remains subjective, requires a lot of labor, and happens only intermittently. Our solution offers something fundamentally different: objective, consistent, continuous insight into how a patient's neurological state is doing. Our pilot program is designed to build practical, hands-on knowledge — validating which patient groups are the right fit, refining how clinical workflows operate, honing our approach to commercialization, and gathering clinical evidence. What we're hearing back from the field is positive. There's been considerable enthusiasm for our delirium offering. What's especially notable is how much that enthusiasm grows when delirium monitoring is combined with seizure detection. That enthusiasm is further reinforced by the study we recently kicked off with Vanderbilt Medical Center, which looks at how seizure and delirium intersect among ICU patient populations. Even on its own, the delirium algorithm offers obvious benefits, yet our belief is that addressing seizures and delirium as a combined problem might reshape how intensive care is delivered. We're also happy to report that this past April brought a favorable proposed ruling from CMS regarding a new technology add-on payment, known as NTAP, covering our delirium monitoring product. Under that proposal, incremental reimbursement could reach as much as $2,171 for each patient. We see this as an encouraging sign that a beneficial final rule may arrive in August 2026. Should it be adopted, the NTAP would take effect on October 1, 2026. Our view is that such a final rule, if favorable, would build on the substantial clinical enthusiasm already surrounding this technology and help clear a path toward its uptake. As we look to the future, our timeline for the delirium solution's full commercial rollout remains unchanged—we're targeting either the fourth quarter of 2026 or the first quarter of 2027. Now, shifting to LVO stroke: back in January 2026, we were granted breakthrough device designation for that indication. Our clinical programs continue to advance, and we're eager to provide updates over the next several quarters. Zooming out, my pride in what this team achieved during the year's first quarter is immense. Q1 strengthened our belief in the path we're on, and the momentum we're bringing into the remainder of 2026 gives me real energy. Business-wide execution is proceeding as planned, with multiple important efforts actually moving faster than anticipated. When we look at the U.S. market by itself, we put the total addressable opportunity at roughly $3.5 billion, which is almost twice the size it was only twelve months back. In our view, no one is better positioned than Ceribell to take the lead here, thanks to an integrated platform, the trust physicians and administrators have placed in us, and clinical evidence that keeps accumulating. What we are aiming for is one unified brain monitoring platform that establishes a fresh benchmark for neurological care, and that vision is what guides our execution. Making EEG a new vital sign remains a commitment we hold, and the early momentum we have seen in 2026 only deepens our belief in how transformational what we are building will prove to be. Having said that, I'll hand things over now to our CFO, Scott Blumberg, so he can walk us through a review of the first quarter's results along with the 2026 guidance.
Thanks, Jane, and good afternoon to all of you. As Jane pointed out, we brought in $26.5 million in total revenue during the first quarter of 2026, up 29% from $20.5 million in the first quarter of 2025. Growth was mainly fueled by greater uptake of the Ceribell System among both new and existing accounts. Product revenue came to $20.2 million in the first quarter of 2026, an increase of 29% over $15.6 million in the first quarter of 2025. Subscription revenue reached $6.3 million in the first quarter of 2026, which is 29% higher than $4.9 million in the first quarter of 2025. We closed Q1 with 680 hospitals in our account base, a gain of 33 accounts during the quarter. That figure includes several accounts tied to our continued expansion inside the VA system; we still expect to add VA accounts incrementally as the year goes on; we're happy with the ongoing sequential momentum we saw in headband purchasing trends during the first quarter, which in our view shows our same-store growth efforts are working, along with our emphasis on launching high-quality new accounts. Although we intend to keep driving deeper within our accounts, I want to remind you that Q2 and Q3 volumes usually moderate on a sequential basis because ICU census drops during the warmer months. Gross margin came in at 87% for Q1 2026, versus 88% a year earlier. We managed that even while depending on inventory brought in from China at a higher tariff rate. A range of cost reduction initiatives we launched in 2025 allowed us to offset nearly all of that expense. Once we get into the back half of 2026, we'll start shipping inventory from our fully operational Vietnam line, which faces lower tariff rates. As a result, we're confident we can keep gross margins in the high 80% range for all of 2026. Total operating expenses were $43.9 million in the first quarter of 2026, rising 36% from $32.2 million in the first quarter of 2025. Noncash stock-based compensation expense came to $3.7 million in the first quarter of 2026. Higher sales and marketing expense during the first quarter stemmed from the investments in our commercial organization that we described earlier. On top of that, our national sales meeting normally happens in Q1, which pushes up non-headcount sales and marketing expense for the quarter. G&A expense rose in Q1 because of costs tied to our ongoing IP litigation, which came to $5.6 million; that's much higher than prior quarters, reflecting how litigation-related activities don't follow a linear pattern. Research and development expense grew in Q1 due to added headcount supporting improvements to our product platform, including work to develop and enhance our new product pipeline. For the first quarter of 2026, our net loss came in at $19.7 million, which works out to a loss of $0.52 per share. That compares with a loss of $12.8 million, or $0.36 per share, in the first quarter of 2025. To calculate loss per share for Q1 2026, we used an average weighted share count of 37.7 million shares. Looking ahead, we're going to start reporting adjusted EBITDA, because we think it better represents how our business is performing on an ongoing basis. Adjusted EBITDA takes our net loss and backs out interest, taxes, depreciation and amortization expense, and it also removes noncash stock-based compensation expense along with legal expenses tied to the IP litigation we're currently involved in. For the first quarter of 2026, adjusted EBITDA loss was $11.2 million, versus $10.9 million in the first quarter of 2025. As of March 31, 2026, our cash, cash equivalents and marketable securities totaled $141.2 million. We're still focused on our goal of reaching cash flow breakeven, and with the cash we have on hand, the strength of our balance sheet and our strong gross margin profile, we have a high degree of confidence in our ability to get there. Now let's turn to our outlook for 2026; for the full year 2026, we expect total revenue to range from $112 million to $116 million, which is up from the $111 million to $115 million we guided to previously. That works out to annual growth of 26% to 30% over 2025; this guidance change reflects the momentum we're seeing in our core business, with success driven both by new account additions and usage within our established account base. With that, I'll hand the call back to Jane.
Thanks, Scott, and I appreciate everyone joining us today. We feel good about how we performed in the first quarter and about where our business is heading; we keep making real strides toward getting our system accepted as the standard of care for detecting seizures in acute care settings. Given that penetration in our core seizure market sits below 4%, there's a considerable runway in front of us. Meanwhile, we're pushing our platform into additional indications with urgency and purpose, working toward a comprehensive brain monitoring system. Making EEG a new vital sign is still our North Star. At this point I'll hand the call to the operator for Q&A. Operator?
I just had a question regarding Q1 and the guidance. Q1 ended up slightly ahead of The Street, and you lifted the guide by $1 million, which is a bit more than the beat. So could you discuss why you decided to raise the guide and how confident you feel about the outlook for the year?
Sure, Stephanie. As far as 2026 goes, our business really has 2 main drivers. Those are account acquisition and same-store growth, and on both fronts we're performing quite well. We just posted our biggest quarter of net new adds since becoming a public company, along with record usage per account. So that's really what underpins our confidence in the business and what allows us to raise guidance coming out of Q1.
Got it. Let me squeeze in one more question, this time on OpEx. The figure landed a bit higher than our model had assumed. Was litigation the main driver there? Or did spending on commercial efforts also come in hotter than you'd anticipated? And with Q1 in the books, does your outlook for the whole year change? Or should we read this mostly as expenses landing in a different period?
We don't provide guidance on OpEx. That said, looking at Q1, sales and marketing along with R&D each ticked up somewhat, and I'd frame that as money put back into the business. Our approach is to keep weighing the facts in front of us and direct funds toward areas that fuel growth down the road — and that includes adding headcount to the sales organization. According to what Jane described, part of that stemmed from the work of our regional health systems group. We also continue putting money into R&D, both for launching new products and for enhancing the ones we already sell. The IP cost actually showed up within G&A. It came to exactly $5.6 million, which is above the level from earlier quarters. That reflects the timing of the litigation, since we're currently in Q1 and Q2, the period carrying the biggest burden as we get ready for trial and head into it; so we would anticipate it easing off as we move toward the latter part of the year.
Lily here, filling in for Robbie. I'd love it if you could expand a little on what you're currently observing in pediatrics and neonates. I realize it's early days yet, but might you share some of the initial feedback and usage patterns you've noticed up to now, plus how significant a role this is expected to play in this year's guidance?
Yes. Broadly speaking, as I said during the call, the momentum we're witnessing is quite positive; every one of the initial neonate pilot sites has agreed to proceed into full execution. Beyond that, we're seeing considerable enthusiasm for neonate expansion among current customers and new ones alike. So that might end up fueling both utilization and the addition of new accounts. When it comes to the pediatric ER, that case I brought up on the call isn't some anomaly. These patients are extremely vulnerable when they arrive at the ER, and doctors frequently face a scenario where EEG isn't obtained and can't be obtained; as a result, we find that physicians and nurses recognize that opening for improvement. All in all, I'd describe the clinical validation as having been really robust. As for the latter portion of your question—what this means for revenue—it remains quite in line with the guidance we've been providing, since even reaching a new department or bringing in an additional patient population can still require months, and for new accounts it can still demand the same level of effort and the same timeline. So we'd anticipate some effect in 2026. What we'd expect is that a considerably more substantial effect would arrive in 2027 and afterward.
Great. Now, as a quick second question about gross margin — it landed very strong, higher than our expectations and beyond the full-year range you had previously guided to. Could you expand on what powered that strength during the quarter and in the guidance? And what portion, if any, comes from tariff refunds?
Let me take the latter part first. Tariff refunds account for none of it; nothing of that sort has been recorded in our financial statements, and we will include it if and when the refund arrives. What's actually behind it are the investments we put into cost mitigation during the prior year. We pursued those partly through normal business operations, but we also put in extra money as tariffs were on their way. That let us offset nearly all of the added tariff expense tied to China. As I noted earlier, we're also producing in Vietnam now and hold that inventory internally; however, under our FIFO method of accounting, it has yet to flow through the income statement. So heading into the latter portion of 2026, there's potential for additional upside there too.
To start, I'd like to stay on neonate briefly and dig a bit deeper — try to pull out additional specifics about how that's progressing. Jane, you brought up that the initial — I believe it was the initial 5 accounts that moved from a pilot into a full launch. Tell us a bit about what those accounts observed that gave them confidence that both you and the accounts could move forward into a full launch. What are you seeing in these early days once it enters a full launch? And once you reach that wider commercial stage, is there any effect and pull-through on the seizure side too?
Yes. Regarding the new accounts, the conversion of pilot accounts, there are usually a couple of things we picked up. First is the neonatologists or the neonate nurses. They guard their patients even more fiercely. So whenever they deploy new technology, they're extremely careful and confirm the new technology causes no harm and is genuinely safe. So across the last couple of months, all of them validated very robust safety, particularly tied to skin integrity for this patient population. They likewise validated how easy it is to use, and a number of them also confirmed the accuracy of Clarity. So given all of that, it converts into very strong clinical buy-in. On the health economic side, a few of these sites aren't Level 4. They may be Level 3. So previously they would transfer patients out since they couldn't obtain EEG; and naturally, they forfeit the reimbursement tied to the patient, and they managed to demonstrate they could potentially leverage this to cut down on those transfers. So that's a very powerful health economics driver on top of the strong clinical driver, plus you don't have patients being moved. So it's quite encouraging that we're witnessing early on our hypothesis of clinical and health economic drivers from our market research becoming the reality we observe in the commercial pilot. And at this point our aim is to further implement and roll out our playbook; and the final thing I'll note is we also observe that the pediatric epileptologists are highly supportive since our montage aligns with the ACNS guidelines, that's the full montage. And they're quite encouraged to see they can view the full picture too and are pleased with the Clarity Assistant. So on the whole, we stay optimistic regarding the full launch.
Great. Perhaps we pivot somewhat toward the account additions front. Your team delivered an excellent quarter on that measure, a record one. I realize you referenced a few distinct categories, yet you've likewise discussed putting money into certain of those corporate-oriented groups, assuming that's the proper label, which tends to pull demand downward from senior levels. Could you perhaps walk us through which 1 or 2 drivers contribute most incrementally to that pace of account additions, and help us grasp how sustainable that will be moving forward.
Yes. That approach grew out of the wins we achieved during the prior year. We saw certain of our strongest TMs who could sign a far larger volume of accounts, since their attention was squarely on the system — regional hospital systems. That's the reason we chose to scale up that demonstrated approach; thus what this group does involves creating several layers. First, they'd concentrate more at the hospital system tier, frequently administrators or the CMOs, the VP overseeing patient transfer, the CFOs, since at the TM tier, typically, they never reach the regional system tier. And the second element they can propel the business with is their ability to align efforts throughout our TM plus CAM organization. because even, let's say, a 10, 20 hospital system, a portion of those are already our accounts. So we have CAM handling that. A portion of those are divided among various territories. Having somebody centralized who coordinates those efforts is likewise a major driver. And the third driver, I'd say, this marks the initial occasion we are running the regional system in a more advanced manner. So on the inside, we track pipeline activity; we ensure the CAM and TM collaborate tightly to also build the pipelines so this hospital system closes. It's premature to share the real outcome since this cycle runs longer. Regional system may require a bit more time than single accounts. Yet based on the early signal, we feel quite confident.
Nice start to the year — congratulations. I'd like to ask about utilization. The trends appear to keep strengthening. You introduced the systematic department expansion initiative in the prior year, and it looks like improvement has grown steadily. Any quantitative or qualitative detail — anything further you could share about that effort and how it affects utilization at same-store accounts?
Yes. I can provide more, and it's likely to lean qualitative. On the whole, our approach hasn't changed; it consists of departmental expansion, engaging physicians and providers across every shift, plus pushing verticalization among differing patient populations. That strong quarter owes partly, as Scott noted, to Q1 being peak seasonality, yet we likewise think a meaningful share stems from execution; in the prior year we also devoted considerable investment toward assembling a very robust regional director leadership team, growing the CAM team in line with that, and sharpening our execution and playbook. I believe much of the work we've invested is now showing, and we're simply watching the team perform superbly. So I feel quite proud of what we've achieved, and of what the team has achieved here.
And one more thing I wanted to ask — my hope was to get a clearer picture of what you, Jane, called a possible synergy, or rather not just possible — there could be, and there will be, a synergistic relationship involving the delirium and seizure indications. You've got this Vanderbilt study underway. Could you expand on how you anticipate the results, or even what the existing body of evidence shows, regarding how, once the delirium launch happens, it might also push deeper penetration for the seizure indication?
Yes. Thanks, Josh. From a clinical standpoint, delirium and seizure are very much intertwined. Perhaps I can illustrate with a single example patient population. Take a sepsis patient who has altered mental status — which applies to many of them — roughly 20%, 30% of these patients, if you monitor them with EEG, would turn out to have non-convulsive seizures. Then 40% to 50% of these patients would have delirium. Yet their symptom, absent EEG, looks identical: the same patient, simply altered mental status. And to complicate matters further, among the 20%, 30% seizure patients, about 40% of them later would have delirium; and among the delirium patients, if you monitor them with EEG, a good portion later would develop seizure. So that's on the prevalence side — some existing publication demonstrated how intertwined they are. Now moving to treatment, as many of us know, benzo is the first-line treatment for status epilepticus for inpatients, and often physicians use it empirically to treat seizure. However, benzo is also the #1 deliriogenic agent. So when patients have delirium, you want to keep them away from benzo. And right now, without an objective tool, physicians again have to guess. So this is why, as we show this clinical evidence and start connecting the dots for the physicians, the light bubble goes on; and many physicians would wonder — I wonder how many of the delirium patients I'm treating actually have non-convulsive seizures. So that's really the initial discussion that led to the study we are initiating with Vanderbilt.
Let's begin with the delirium launch as you move into the pilot phase — do you expect to be able to bill for delirium on its own? Or is it more likely that this becomes one of the things you measure metrics on, simply helping you grow your installed base and strengthen your defensive moat versus competitors? Any broad thoughts as you head into this? Will it bring in incremental revenue? Or does it mainly help you keep landing, expanding, and truly dominating the market?
Yes. Thanks, Bill. What you're highlighting is 2 possible drivers behind your question. First, we might charge a higher amount, or a separate amount, for delirium, which would make it a revenue driver. Second, by providing a delirium solution, even within existing accounts, we might generate greater patient usage; so indeed both are possible drivers for launching delirium. Right now, we recognize that we hold both options. We haven't made the decision and aren't prepared to talk about how pricing will work yet. But that is precisely the reason we're running the delirium pilot — to examine both price elasticity, or sensitivity, and what effect delirium could have on the amount of patient expansion we can reach. So we hope to likely talk more about the topic you raised later on, once we're prepared to launch delirium in full.
Great. Now I'd like to revisit the guidance topic. It's not often that a company exceeds expectations by $600,000 to $700,000 and subsequently lifts its guidance by $1 million, particularly following the first quarter. You've explained this is due to the sales force gaining momentum. However, the remarks about seasonality in Q2 and Q3 leave me somewhat puzzled. I suppose the clearest way to put it is: from a cadence perspective, the consensus figure for the second quarter stands at $27.2 million. Do you feel at ease with that figure? Any input or remarks would be much appreciated.
My view is that the seasonality remark isn't anything new—it serves more as a reminder. I think most of the Street has correctly incorporated the seasonal pattern where Q4 and Q1 come in higher than Q2 and Q3. So, regarding that particular quarter's consensus, I won't offer a specific comment, except to say that I believe people grasp the seasonality. I'd also separate these two things. Naturally, the guidance we provide covers the entire year, and our confidence in the full year is quite strong. We simply want to ensure everyone is properly considering the shift from Q1 into Q2, which historically has been—and we anticipate will remain—a sequential decline in usage per account. Naturally, the growth initiatives we're undertaking, involving both new customer additions and the effect of the cans, work to counterbalance that.
I'd like to revisit the topic of how productive the sales team is. You shared some really useful figures, and it's quite encouraging that among those with a year or more on the job, more than 85% have added to the account base, and every single one of them has brought in purchase orders. I just want to verify, given this is the first quarter we're seeing this kind of data, whether it's all fairly recent — once people reach that 12-month mark, they begin contributing this way due to how long the cycle runs? Essentially, what I'm asking in a roundabout way is: how much time is needed before a rep reaches maximum productivity in terms of time on the job, and perhaps there isn't even a limit? Any insight into what we might expect going forward would be helpful.
Yes. Of course, Marie. To start, let me be clear that adding new reporting metrics isn't our plan. We simply wanted to put numbers behind something we'd been describing in qualitative terms for some time, since we've now reached the stage where the reps involved in that expansion — which really got underway near the close of Q3 2024 and the start of Q4 — are arriving at this point. Typically, we've anticipated that a rep would land their first new add at roughly the one-year mark; that pattern has held steady. Our last significant broadening of the sales team was back in 2021. Naturally, we've brought on reps since then as well. The breakdown works out to roughly 2 or 3 months for training a rep, around 6 months to secure a purchase order, and 3 or 4 months for launch. Altogether, that comes to roughly a year; and over the last 1.5 years, ever since that expansion began, we've been monitoring the early indicators — namely, the CRM tracking of the activities we understand tie to purchase orders. Now we've arrived at a stage where we can turn that into something concrete for you; so we figured we'd offer a peek behind the scenes at how it's shaping up. I should also note that it's a fairly limited group, given that the expansion unfolded across a year, and this represents just the initial segment of them, though the others are on the same trajectory. That's among the reasons we feel good about generating stronger growth this year compared to last year, since we have quite a few people maturing into productivity as the year progresses.
Okay, that was really helpful, Scott. I've got just one brief follow-up — I'd like some clarity regarding seasonality. Naturally, I realize that the number of beds occupied in the ICU could affect utilization for each account. However, should we anticipate any effect on the accounts we add? From my perspective, it appears you would still be capable of making sales into those departments. I simply wanted to get that cleared up.
Right. We don't have any particular seasonal pattern. What we do observe is a modest amount of unevenness from one quarter to the next, and that could grow later on once the new regional health system function is added, since accounts will arrive in larger batches; so there isn't — no steady pattern exists, yet you can watch it rise or fall provided the overall trajectory goes upward and to the right; that's what happened last year, when I believe Q2 came in below Q1 while Q3 was far above Q1. It fluctuates somewhat, but the direction is toward adding more.
To start, might you discuss military hospitals and address what kind of opportunity and TAM they represent, especially regarding how large and broad the VA network is?
Sure. When it comes to how many hospitals, our grasp of the military hospital count is roughly 30 or so. That is far below the 170 hospitals in the VA. It's an opportunity that carries real significance. Their cybersecurity setup actually differs somewhat from what VA uses. Even so, the cybersecurity overlap is greater. That let us take the wins achieved at VA and get physicians along with administrators to back and adopt the cybersecurity progress made via the FedRAMP hike, plus the VA success, to launch this pilot. On the clinical side of unmet needs, the challenges they confront closely mirror those at VA, with insufficient neurologist resources and neurologist availability standing out as one, and EEG technicians too; so at present, our attention stays on military hospitals, and we feel enthusiastic about the possible upside this could deliver.
Understood, that helps. Could you expand a bit more on what you said about CAT scans? I'm just interested in the way some of these pathways and triage monitoring function when stroke and LVO patients are being evaluated with respect to CTs and MRIs.
Let me just confirm I've got the question right — you're asking how our LVO monitoring algorithm would function as a complement to CT and MRI, and other imaging tools.
Exactly. So in real-world use, what kind of protocol or standard of care do you imagine?
Yeah. Of course, it's still a bit soon for us to discuss the precise workflow. But how we view the product's value proposition is this: we aren't replacing any CT or MRI as the gold standard for LVO detection. In the inpatient setting, what we see as our product's value proposition is that continuous monitoring piece, which could let us potentially triage and spot LVO more quickly. And with CT and MRI, you can't simply keep sending patients to those machines constantly, correct? So if a continuous monitor is available, we could say this patient has a very, very high likelihood of having large vessel occlusion, and that could potentially set off a workflow to send the patient for CTA or MRIs as needed to confirm LVO. And so that could significantly shorten the delay of LVO detection. I hope that answers your question.
Perhaps only two quick items. I understand this might hinge on — well, it's going to hinge on how big a hospital is, but when it comes to utilization at VA hospitals versus non-VA hospitals, what direction would you anticipate that taking, assuming there's any difference at all?
We don't share utilization at the level of individual hospital systems, since although we've discussed VA as an opportunity largely due to FedRAMP High, which unlocked a sizable system, when it comes to public disclosure, we simply don't reveal utilization figures for any particular system.
All right. All right; regarding that $5.6 million of litigation expense this quarter, Scott, does that represent the peak — and just to confirm, does that $5.6 million compare with roughly $1 million per quarter across the prior few quarters? Have I got that right?
Previously we were averaging somewhere between $1 million and $2 million each quarter. And as we proceed through the year, with the comparison period and adjusted EBITDA, you'll be able to follow that. So Q1 came in outsized. Q2 probably will be higher as well. We're right in the peak portion of the activity, with depositions and trials coming up; so I'd anticipate Q2 being elevated too, and after that it will begin to moderate as you get further into 2026.
Well, thanks to all of you for being on this call. As a team, I feel a great deal of pride in what we've achieved, and I'm quite enthusiastic about what lies ahead, and I can't wait to share additional milestones in the quarters to come.
Everyone, that brings us to the end of today’s call. Thanks to each of you for being here. You’re welcome to disconnect at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete CeriBell, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to CeriBell, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.